Blood flow restriction exercise program for people with peripheral arterial disease
Official title: REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center
Run by University of Tennessee Graduate School of Medicine · NCT07223437 · Data updated 2026-11-12
This will test whether supervised blood flow restriction (BFR) resistance exercise helps adults with peripheral arterial disease walk farther and feel better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 81 (estimated) |
| Sponsor | University of Tennessee Graduate School of Medicine Academic / other |
| Locations | 1 site (Knoxville, Tennessee) |
| Status | Recruiting |
| Started | April 27, 2026 |
| Main results expected | April 27, 2027 |
| Study ends | April 27, 2027 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT07223437 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with diagnosed PAD and stable claudication for at least six months, an ankle-brachial index of 0.4–0.9, and eligibility for cardiovascular or pulmonary rehabilitation are ideal candidates.
✕Probably not a fit
People with unstable cardiac conditions, recent acute cardiac or pulmonary events, symptomatic severe valvular disease, acute thrombophlebitis, or physical disabilities that prevent safe exercise are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This feasibility study compares supervised BFR low-load resistance training with low-load and high-load resistance training in adults with peripheral arterial disease. Participants will undergo a supervised exercise program using a BFR cuff system and standard resistance training protocols, with outcomes measured at baseline, post-intervention, and 3-month follow-up. Primary functional outcome is change in Six-Minute Walk Test distance, and quality of life will be measured with the EQ-5D-5L; safety and adverse events will also be tracked. The trial is conducted at the University of Tennessee Medical Center and is intended to inform larger trials if feasible and safe.
Why it matters
Potential benefit: If successful, this approach could help people with PAD improve walking distance and quality of life using lower-intensity resistance exercise.
How similar studies have gone: BFR training has shown promise for improving strength and function in other patient groups, but its application in PAD is relatively novel with only limited preliminary data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years of age or older 2. Diagnosed peripheral arterial disease with stable claudication (symptomatic presentation unchanged for 6 months) 3. Ankle-brachial index (ABI) between 0.4 and 0.9. 4. Eligible referral to cardiovascular or pulmonary rehabilitation 5. Prior revascularization permitted if symptoms are stable and other criteria are met Exclusion Criteria: 1. Recent change in resting ECG suggesting significant ischemia, recent myocardial infarction (within 2 weeks), or another acute cardiac event 2. Unstable angina 3. Uncontrolled cardiac arrhythmias 4. Symptomatic severe aortic stenosis or other significant valvular disease 5. Decompensated symptomatic heart failure 6. Acute pulmonary embolism or infarction 7. Acute noncardiac disorder likely to interfere with or be worsened by exercise (e.g., infection, thyrotoxicosis) 8. Acute myocarditis or pericarditis 9. Acute thrombophlebitis 10. Physical disability precluding safe or adequate exercise performance 11. Significant electrolyte abnormalities 12. Clinically significant tachyarrhythmias or bradyarrhythmias 13. High-degree atrioventricular block 14. Atrial fibrillation with uncontrolled ventricular response 15. Hypertrophic obstructive cardiomyopathy with resting left ventricular outflow gradient of \>25 mmHg 16. Known active aortic dissection 17. Severe resting arterial hypertension (SBP\>200mmHg or DBP \>110 mmHg) 18. Mental impairment preventing cooperation with study procedures 19. Current pregnancy 20. Moderate to severe peripheral neuropathy 21. Open wounds or compromised skin near BFR cuff site 22. Active DVT or thromboembolic event within the past year
Where it's running
-
University of Tennessee Medical Center
Knoxville, Tennessee, United States Recruiting
Study contacts
- Study coordinator: Tiffany Johnson, Study Coordinator
- Email: thjohnson@utmck.edu
- Phone: +1865-305-4682
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
Predictors of Major Adverse Limb Events After Iliac Artery Stenting
This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.
-
New prodrug CG-0255 Besylate vs Plavix in healthy adults
This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.
-
Radial and Ulnar Access in Vascular Interventions Registry
This registry tests how often radial or ulnar artery access is used and what happens afterward in routine vascular procedures.
-
Remote versus in-person 30-second sit-to-stand testing for people with peripheral artery disease
This project will test whether doing the 30-second sit-to-stand test by video works as well as doing it in person for adults aged 18–65 with Fontaine stage I–II peripheral artery disease who have a smartphone.
-
Imaging plaque activity across the body in people with symptomatic peripheral arterial disease
This project will use whole-body PET-CT and CT angiography with several tracers to see if imaging can detect inflammation, microcalcification, and clot activity in people with symptomatic peripheral arterial disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.